ArticleCureus2026
The Rare Case of a Sertoli Cell Tumor of the Adrenal Gland in a Man With Pathological Dexamethasone Suppression Test: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sertoli cell tumors are rare gonadal stromal tumors. Extragenital manifestations, particularly in the adrenal gland, are exceptionally uncommon. We present a case of an adrenal Sertoli cell tumor in a male patient, presenting with a pathological (1 mg overnight) dexamethasone suppression test. An 82-year-old otherwise healthy man was referred for evaluation of an incidentally detected left adrenal mass. The patient was asymptomatic with no clinical signs of catecholamine excess, hypercortisolism, hyperaldosteronism, or B-symptoms. Initial CT scan revealed a 44 × 42 mm lesion, which increased to 50 × 46 mm within three months and showed suspicious washout characteristics. Endocrinological work-up showed a pathological (1 mg overnight) dexamethasone suppression test, while metanephrines and aldosterone testing were normal. Tumor markers [alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (β-HCG)] were unremarkable. A hormonally active adrenal adenoma with autonomous cortisol production was suspected. After discussion at the interdisciplinary tumor board, robotic-assisted adrenalectomy was performed. Complete resection was achieved without complications; the patient was discharged on the third postoperative day. Histopathological examination showed a Sertoli cell tumor with complete excision and no evidence of local infiltration or malignancy. Immunohistochemistry showed positivity for cluster of differentiation (CD)56, CD99, synaptophysin, and partial positivity for SF1, calretinin, and inhibin. Chromogranin A and MART1 were negative. Molecular analysis revealed no FOXL2 or DICER1 mutations. Postoperatively, hydrocortisone replacement was initiated due to a submaximal cortisol response to adrenocorticotropic hormone (ACTH) stimulation testing. At six-month follow-up, CT imaging showed no recurrence or metastases, and tumor markers remained normal. Adrenal Sertoli cell tumors represent an extremely rare entity lacking specific management guidelines. In this case, robotic-assisted adrenalectomy proved safe and feasible. We observed good short-term oncological and clinical outcomes. Further reports are needed to clarify hormonal associations and establish standardized follow-up and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.